Clinical trial • Phase III • Endocrinology
NNC0487-0111 for Type 2 diabetes
Phase III trial of NNC0487-0111 for Type 2 diabetes. 80 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 09-01-2026
- First CTIS Authorization Date
- 09-03-2026
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 80
Recruitment
- Planned Sample Size
- 80
- Recruitment Window Months
- 20
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 80
Germany
- Earliest CTIS Part Ii Submission Date
- 12-02-2026
- Latest Decision Or Authorization Date
- 28-04-2026
- Processing Time Days
- 75
- Number Of Sites
- 1
- Number Of Participants
- 80
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Patrick Fischer
- Contact Person Email
- patrick.fischer@profil.com
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- NNC0487-0111
Related trials
Other published trials that may interest you.